Sunday, February 25, 2018 5:10:29 AM
CAR-T-Meso
Metastatic Pancreatic (Ductal) Adenocarcinoma
Epithelial Ovarian Cancer
Malignant Epithelial Pleural Mesothelioma
HTTPS://clinicaltrials.gov/ct2/show/NCT02159716
Even more to come
The latest exciting developments with CAR-T are still ringing in the ears of the industry and the good news is expected to keep coming. Novartis is far from done, with a slew of plans ready to unfold in the space, as Althoff outlined: “We are excited about the possibility of CAR-Ts to transform cancer care. Kymriah is just the first of Novartis' CAR-T cell therapies. The company also plans to file Kymriah with the FDA in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), as well as file applications with the European Medicines Agency for both B-cell ALL and DLBCL by the end of this year.
“As part of the company’ ongoing research and development collaboration with Penn, together we’ve generated CTL119 – a humanised anti-CD19 CAR – which is in initial clinical development for multiple B-cell malignancies,” he continued. “We’re also studying CART-BCMA, a novel, fully human CAR targeting BCMA, in multiple myeloma and CD123 CAR-T in myeloid leukaemia. Additionally we are studying a number of other CAR therapies in solid tumours, including a humanised anti-EGFRvIII CAR for Glioblastoma Multiforme, a lethal and common brain cancer, and a fully human anti-Mesothelin CAR (huCART-Meso) which recently began clinical testing.”
CAR-T Type Cancer indication Phase 1 Phase 2/ pivotal Phase 3 Submitted Approved
CD19 CAR-T Pediatric & young adult r/r ALL1 EU US
CD19 CAR-T r/r DLBCL2 US/EU
CD19 CAR-T DLBCL in 1st relapse2 Starting 2018
CD19 CAR-T r/r FL3 Starting 2018
CD19 CAR-T r/r DLBCL2
in combination
with pembrolizumab Starting 2018
CD19 CAR-T CLL4 Starting 2018
CAR-T-BCMA r/r Multiple Myeloma Starting 2018
CAR-T-EGFRvIII Recurrent GBM5 Started
CAR-T-Meso Advanced ovarian cancer,
Mesothelioma Started
Novartis has one of the most comprehensive CAR-T
development programs across multiple large indications
1. ALL – acute lymphoblastic leukemia 2. DLBCL – diffuse large B-cell lymphoma
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM